Russell Schundler Sells 2,060 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 2,060 shares of the firm's stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the sale, the general counsel now owns 486,027 shares of the company's stock, valued at approximately $7,086,273.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total value of $136,890.46.

Liquidia Trading Up 2.1 %

Shares of NASDAQ LQDA traded up $0.28 during midday trading on Wednesday, hitting $13.86. 658,239 shares of the company's stock were exchanged, compared to its average volume of 947,129. The business's fifty day moving average price is $14.75 and its two-hundred day moving average price is $10.95. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -11.55 and a beta of 0.16. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The company had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. Equities analysts expect that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Fortitude Family Office LLC bought a new stake in Liquidia in the fourth quarter worth $26,000. Tower Research Capital LLC TRC increased its stake in Liquidia by 101.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company's stock worth $55,000 after purchasing an additional 3,524 shares during the period. UBS Group AG lifted its position in Liquidia by 134.0% in the second quarter. UBS Group AG now owns 7,948 shares of the company's stock valued at $35,000 after purchasing an additional 4,552 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Liquidia during the second quarter valued at approximately $38,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Liquidia by 610.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company's stock worth $108,000 after buying an additional 7,731 shares during the period. Institutional investors own 64.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LQDA shares. HC Wainwright boosted their price objective on Liquidia from $16.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, March 14th. Wedbush reaffirmed an "underperform" rating and issued a $3.00 price target on shares of Liquidia in a report on Thursday, December 21st. Bank of America boosted their price objective on Liquidia from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, December 21st. LADENBURG THALM/SH SH raised their target price on Liquidia from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, December 21st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of Liquidia in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).